Arcutis Biotherapeutics, Inc.
NASDAQ:ARQTBiotechnology
-$0.51 today
- Market cap
- $3.49B
- Beta
- 1.52
- P/E (TTM)
- -1400.0
- EPS (TTM)
- -$0.02
Volume 0.84M
Average 1.61M
ARQT Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Arcutis Biotherapeutics, Inc.NASDAQ: ARQT
Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026
Stock-based compensation growth accelerates
Q2 FY2026 stock-based compensation of $12.76M rose 21.7% year over year, ahead of the +10.4% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 19.4% from the prior quarter. Over 3 fiscal years it compounded at +7.3% a year.
Context
- Stock-based compensation amounted to 10.7% of revenue in FY2025, down 10.5 pp from a year earlier.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +21.7% holds above the trailing-twelve-month pace of +10.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 40.36M USD
- Year-over-year change
- -3.3%
- 4-year CAGR
- +14.0%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 40.36M | -3.3% |
| FY2024 | 2024-12-31 | 41.73M | +7.5% |
| FY2023 | 2023-12-31 | 38.81M | +18.8% |
| FY2022 | 2022-12-31 | 32.68M | +36.8% |
| FY2021 | 2021-12-31 | 23.89M | — |
Stock-Based Compensation vs competitors
How ARQT compares with its peers on the latest reported figures
- ARQT's LTM Jun 2026 stock-based compensation of $43.55M is the largest of the 6 companies compared; the peer median is $2.13M.
- Its year-over-year change of +10.4% is the highest of 3, against a peer median of -34.4%.
- Stock-based compensation amounts to 9.4% of revenue for ARQT, versus a peer median of 32.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $43.55M | +10.4% | +7.3% | 9.4% | |
| LTM Mar 2026 | $12.05M | -2.1% | -6.3% | 144.0% | |
| LTM Mar 2026 | $2.88M | -66.7% | -9.8% | — | |
| LTM Jun 2024 | $2.13M | — | — | 32.5% | |
TTRXTurn Therapeutics Inc. | LTM Mar 2026 | $0 | — | — | — |
EVMNEvommune, Inc. | LTM Mar 2026 | $0 | — | — | 0.0% |
| Peer median (excluding ARQT) | $2.13M | -34.4% | -8.0% | 32.5% | |
Competitors are the stored peer set for ARQT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (206.36M) | (311.46M) | (262.14M) | (140.04M) | (16.14M) |
| Depreciation & Amortization | 454K | 934K | 750K | 2.6M | 4.67M |
| Deferred Income Tax | 3.45M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 23.89M | 32.68M | 38.81M | 41.73M | 40.36M |
| Change in Working Capital | 3.62M | (10.18M) | (23.5M) | (15.08M) | (34.83M) |
| Accounts Receivables | 0 | (8.46M) | (17.35M) | (47.26M) | (73.16M) |
| Inventory | 0 | (7.51M) | (5.62M) | (400K) | (7.33M) |
| Accounts Payables | 245K | 1.57M | 3.15M | 2.23M | (1.69M) |
| Other Working Capital | 3.38M | 4.23M | (3.68M) | 30.35M | 47.36M |
| Other Non-Cash Items | 309K | 30.3M | (979K) | (1.37M) | 314K |
| Operating Cash Flow | (174.63M) | (257.72M) | (247.06M) | (112.16M) | (5.63M) |
| Capital Expenditures | (995K) | (23.28M) | (428K) | (143K) | (686K) |
| Acquisitions (Net) | 74.96M | 22.95M | 0 | 0 | 0 |
| Purchases of Investments | (292.51M) | (415.39M) | (225.84M) | (254.82M) | (246.99M) |
| Sales of Investments | 217.55M | 351.47M | 406.5M | 288.78M | 227.42M |
| Other Investing Activities | (74.96M) | (22.95M) | 0 | (5M) | (10M) |
| Investing Cash Flow | (75.95M) | (87.2M) | 180.23M | 28.82M | (30.25M) |
| Debt Repayment | 73.99M | 125M | 0 | (100M) | 0 |
| Common Stock Issued | 207.49M | 176.05M | 98.9M | 161.68M | 6.97M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 470K | 751K | 2.42M | 4.52M | 0 |
| Financing Cash Flow | 281.95M | 301.8M | 101.32M | 66.2M | 6.97M |
| Effect of Forex Changes | 0 | 0 | (50K) | (235K) | 168K |
| Net Change in Cash | 31.37M | (43.12M) | 34.45M | (17.37M) | (28.74M) |
| Free Cash Flow | (175.62M) | (281M) | (247.49M) | (112.3M) | (6.31M) |
Arcutis Biotherapeutics, Inc.
NASDAQ:ARQT
Intrinsic Alpha fair value
Locked
Current Price
$27.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.